Intel stock extends gains after report of possible U.S. government stake
SAN DIEGO - QuidelOrtho Corporation (NASDAQ:QDEL), a $1.82 billion market cap diagnostics company, launched a Certified Analyzer Program on Wednesday aimed at expanding diagnostic testing access to underserved communities across the United States. According to InvestingPro data, while the company faces near-term profitability challenges, analysts expect positive net income growth this year.
The initiative targets rural and community hospitals with fewer than 100 beds, clinics, and physician office labs, offering certified VITROS analyzers at reduced costs while maintaining quality standards. With annual revenue of $2.74 billion and a healthy gross margin of 47.29%, the company appears well-positioned to support this strategic initiative.
"By repurposing and rigorously certifying high-performing analyzers, we aim to expand access to reliable diagnostic technology for healthcare facilities that play a critical role in their communities," said Audra Jones, Senior Vice President, North America at QuidelOrtho.
Each analyzer undergoes a comprehensive certification process at the company’s Rochester facility, including over 140 system checks, functional adjustments, hardware cleaning or replacement, and performance testing. The certified equipment comes with a 12-month warranty on service and support.
The program features certified VITROS XT 7600 and 5600 Integrated Systems and the VITROS 3600 Immunodiagnostic System, which support community labs running general chemistries, immunoassay tests, and drugs of abuse screening.
According to the company’s press release statement, the initiative aims to provide diagnostic solutions at a fraction of the cost of new equipment while maintaining reliability standards.
QuidelOrtho, a provider of in vitro diagnostics, develops testing solutions across immunoassay, molecular testing, clinical chemistry, and transfusion medicine fields. InvestingPro analysis suggests the stock is currently trading below its Fair Value, with additional insights available in the comprehensive Pro Research Report, which provides deep-dive analysis of this and 1,400+ other US stocks.
In other recent news, Quidel Ortho reported an impressive second quarter of 2025, with earnings per share (EPS) reaching $0.12, significantly surpassing the forecast of $0.0015. This represents a 7900% surprise, with revenue slightly exceeding expectations at $614 million. Raymond James, while maintaining an Outperform rating on Quidel, lowered its price target from $60.00 to $55.00. The firm’s decision followed what it described as "another strong and fairly clean quarter" for the company. Quidel’s revenues were generally in line with expectations, with notable performance in the Labs segment. However, there was a timing-related shortfall in non-respiratory point-of-care products. Despite the robust earnings, the stock experienced a decline, indicating mixed investor sentiment. These developments highlight recent financial and analytical assessments of Quidel Ortho.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.